US EditionZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm
- Rosen Law Firm filed a securities class action lawsuit against Zenas BioPharma, Inc. Following its September 2024 IPO on NASDAQ under ticker ZBIO.
- The lawsuit alleges that Zenas BioPharma’s Registration Statement contained false and misleading statements overstating the duration of its operational funding.
- Investors who acquired securities linked to the Registration Statement may have incurred losses due to alleged misrepresentations, and Rosen Law Firm is urging them to take action to be considered for lead plaintiff status before the court’s deadline in mid-June 2025.
- Rosen Law Firm secured over $438 million in securities settlements in 2019 and Laurence Rosen was named a Titan of Plaintiffs' Bar in 2020 by Law360.
- The pending case may entitle investors to compensation through contingency fees without out‑of‑pocket costs, with a lead plaintiff able to direct litigation on behalf of the class.
47 Articles
47 Articles
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, May 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and…
#Navigating Legal Waters and Market Challenges The Case of Iovance Biotherapeutics,
A Balanced Perspective on the Legal Proceedings Facing Iovance Biotherapeutics and Its Market Position for CSIMarket.com Context and Legal Developments Iovance Biotherapeutics, Inc. a biotechnology company focused on the development of novel cancer immunotherapies, has been thrust into the spotlight due to legal challenges. On May 21, 2025, Rosen Law Firm, a prominent global investor rights law firm, announced the filing of a class action lawsui…
Coverage Details
Bias Distribution
- 56% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
